FAQ on Clene's Presentation at the Emerging Growth Conference

What is Clene Inc. presenting at the Emerging Growth Conference?

Clene Inc. will present its work on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including details on its investigational therapy CNM-Au8(R).

When is Clene’s presentation at the Emerging Growth Conference?

Clene’s presentation is scheduled for 2:20 p.m. on June 12, 2024.

How can I watch Clene’s presentation at the Emerging Growth Conference?

Interested parties can register and view the webcast at https://ibn.fm/A217J or visit the Events section of Clene’s website at https://invest.clene.com/news-events/events.

What is CNM-Au8(R)?

CNM-Au8(R) is an investigational first-in-class therapy by Clene that aims to improve central nervous system cells’ survival and function by targeting mitochondrial function and the NAD pathway, while reducing oxidative stress.

What neurodegenerative diseases does Clene focus on?

Clene focuses on treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis.

Where is Clene Inc. based?

Clene Inc. is headquartered in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.

Will there be a replay of Clene’s presentation?

Yes, a replay of the presentation will be available, with details provided in the announcement.

How can I get more information about Clene Inc.?

For more information, visit Clene’s website at www.Clene.com or contact IBN (InvestorBrandNetwork) at Editor@InvestorBrandNetwork.com.

What is the significance of Clene’s presentation at the Emerging Growth Conference?

The presentation is an opportunity for Clene to showcase its innovative research and therapies for neurodegenerative diseases, potentially attracting investors and partners interested in mitochondrial health and neuronal protection.